血清miR-22 miR-98-5p表达与非小细胞肺癌三维适形放疗疗效的关系研究

doi:10.3969/j.issn.1006-6233.2024.09.019

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1269 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To observe the differences in the expression levels of microRNA (miR)-22 and miR-98-5p in patients with non-small cell lung cancer (NSCLC) and different efficacies after three-dimensional conformal radiotherapy, and to analyze the association between expression levels and efficacy.Methods: A total of 104 patients with NSCLC who were admitted to the hospital from January 2020 to January 2024 were enrolled. All patients received three-dimensional conformal radiotherapy. After radiotherapy completion, the expression levels of miR-22 and miR-98-5p were determined by real-time fluorescence quantitative PCR. One-way analysis of variance was used to analyze the differences in the expression levels of miR-22 and miR-98-5p in patients with different efficacies. Spearman correlation analysis was applied to investigate the correlation with radiotherapy efficacy. The logistic multivariate regression model was adopted to analyze the related factors affecting the efficacy of radiotherapy. The receiver operating characteristic (ROC) curve was drawn to explore the evaluated efficiency of miR-22 and miR-98-5p expression levels on the effectiveness of radiotherapy.Results: There were statistically significant differences in the expression levels of miR-22 and miR-98-5p among patients with different efficacies (P<0.05). There was a statistical significance in the expression level of miR-22 between the SD group and the PD group (P<0.05). The expression levels of miR-22 and miR-98-5p revealed statistical differences in the CR group and PR group compared with those in the SD group and PD group (P<0.05). There were statistical differences in the expression levels of miR-22 and miR-98-5p between CR group and PR group (P<0.05). Univariate analysis showed that different pathological types, TNM stages, differentiation degrees, and expression levels of miR-98-5p and miR-22 were related to the efficacy of radiotherapy (P<0.05). Logistic regression model analysis revealed that TNM staging (OR=3.360, 95%CI:1.229-9.184), differentiation degree (OR=2.779, 95%CI:1.066-7.246), miR-98-5p expression level (OR=2.085, 95%CI:1.147-3.792), and miR-22 expression level (OR=0.590, 95%CI:0.368-0.946) were the influencing factors for evaluating the efficacy of radiotherapy (P<0.05). ROC curve suggested that the areas under the curves (AUCs) of miR-98-5p and miR-22 in evaluating the effectiveness of radiotherapy were 0.798 and 0.800, respectively, the sensitivities were 0.589 and 0.630, and the specificities were 0.871 and 0.839 respectively. The AUC of miR-98-5p+miR-22 was 0.895, significantly higher than that of a single indicator (P<0.05), and the sensitivity and specificity were 0.726 and 0.935.Conclusion: There are some differences in the expression levels of serum miR-98-5p and miR-22 among patients with different efficacies after three-dimensional conformal radiotherapy for NSCLC, and the expression levels are significantly related to the effectiveness of radiotherapy and have certain evaluated value on efficacy.

Key words： Non-small cell lung cancer Three-dimensional conformal radiotherapy miR-22 miR-98-5p Correlation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TANG Yu
	ZHAO Yukui
	SUN Zhu

Cite this article:

TANG Yu,ZHAO Yukui,SUN Zhu. Relationship between Expressions of Serum miR-22 and miR-98-5p and Efficacy of Three-Dimensional Conformal Radiotherapy for Non-Small Cell Lung Cancer[J]. HeBei Med, 2024, 30(9): 1514-1518.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2024.09.019 OR http://www.hbyxzzs.cn/EN/Y2024/V30/I9/1514

[1] Alexander M,Kim SY,Cheng H.Update 2020:management of non-small cell lung cancer[J].Lung,2020,198(6):897-907.
[2] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesr[J].CA Cancer Clin,2021,71(3):209-249.
[3] Kumar M,Sarkar A.Current therapeutic strategies and challenges in nsclc treatment:a comprehensive reviewr[J].Exp Oncol,2022,44(1):7-16.
[4] 李光烈,阎英.非小细胞肺癌放射敏感性标志物[J].国际肿瘤学杂志,2020,47(4):236-239.
[5] Ke SB,Qiu H,Chen JM,et al.ALG3 contributes to the malignancy of non-small cell lung cancer and is negatively regulated by MiR-98-5pr[J].Pathol Res Pract,2020,216(3):152761.
[6] 蒋如如,赵川.miR-22与肿瘤[J].中国生物制品学杂志,2020,33(7):832-836.
[7] Zhong M,Fang Z,Guo W,et al.Translation regulatory long non-coding RNA 1 negatively regulates cell radiosensitivity via the miR-22-3p/SP1 axis in non-small cell lung cancerr[J].Clin Respir,2024,18(1):13734.
[8] 陆舜,纪文翔,虞永峰.2014版《NCCN非小细胞肺癌临床实践指南》更新解读[J].中国医师进修杂志,2015,38(5):318-320.
[9] 王敏,苗玲,赵之寒.非小细胞肺癌患者瘤组织LncRNA LINC00460,miR-98-5p的水平及临床意义[J].广东医学,2023,44(11):1368-1373.
[10] Wang Z,Han Z,Zhang L,et al.MicroRNA-98-5p regulates the proliferation and apoptosis of A549 cells by targeting MAP4K3r[J].Oncol Lett,2019,18(4):4288-4293.
[11] 蒋庆锋,于永魁,程金华,等.LncRNA HEIH通过miR-98-5p调节肺癌细胞增殖和凋亡[J].基础医学与临床,2020,40(1):30-36.
[12] Xia S,Wang C.Hsa_circ_0003489 drives PTX resistance of human NSCLC cells through modulating miR-98-5p/IGF2r[J].Pharmgenomics Pers Med,2023,16:805-815.
[13] Centomo ML,Vitiello M,Poliseno L,Pandolfi PP.An immunocompetent environment unravels the proto-oncogenic role of miR-22r[J].Cancers (Basel),2022,14(24):6255.
[14] Yu Y,Mao L,Lu X,et al.Functional variant in 3'UTR of FAM13A is potentially associated with susceptibility and survival of lung squamous carcinoma[J].DNA Cell Bio,2019,38(11):1269-1277.
[15] 叶广彬,罗世官,张忠伟,等.血清miR-22检测在非小细胞肺癌预后中的临床价值研究[J].安徽医科大学学报,2022,57(3):488-492.